Neurocrine Biosciences Cash Flow - Annual (NASDAQ:NBIX)

Add to My Stocks
$117.36 $1.12 (0.95%) NBIX stock closing price Sep 17, 2018 (Closing)

The Neurocrine Biosciences cash flow statement is one of the three reports that the company generates every quarter. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Neurocrine Biosciences profits and Neurocrine Biosciences debt. This statement can tell if a company is running out of money while still being profitable and is useful in Neurocrine Biosciences stock analysis. Neurocrine Biosciences had a negative net income cash flow of $-142.54M for the latest 2017. This report is very useful in measuring the short term viability of a company. NBIX decrease in investments stood at a value of $-250.87M for the latest year 2017.

View details of Neurocrine Biosciences cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
-142.54M-141.09M-88.92M-60.54M-46.09M5.02M37.57M-7.96M-51.03M-88.61M
Depreciation Depletion Amortization Cash-Flow15.94M4.97M7.04M4.61M3.51M3.79M3.03M2.26M3.17M7.61M
Net Increase (Decrease) in Assets Liabilities-8.8M5.78M8.7M1.6M12.23M-13.36M-4.08M-8.48M-12.38M-12.02M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net41.07M24.15M35.18M7.17M--30.74M-37.2M64.12M7.14M18.85M
Net Cash from (used by) Operating Activities
-94.33M-106.18M-37.99M-47.14M-29.6M-35.29M-0.68M49.94M-53.09M-74.17M
Increase (Decrease) in Prop Plant And Equipment-6.93M-4.09M-1.92M-1.56M-0.5M-0.93M-0.5M-1.15M-0.71M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-244.32M117.05M-193.92M-103.41M5.95M-33.79M-4.83M-54.94M10.81M45.14M
Other Cash Inflow (Outflow) from Investment Activities--0.09M--0.38M-0.1M-0.02M1.79M---
Net Cash from (used by) Investment Activities
-250.87M112.86M-195.81M-105.36M5.34M-34.76M-3.54M-54.7M12.05M44.42M
Issuance (Purchase) of Equity Shares13.86M2.39M276.99M138.73M5.3M83.7M-21.48M9.9M-
Issuance (Repayment) of Debt Securities502.78M---------1.48M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
516.64M2.39M276.99M138.73M5.3M83.7M-21.48M9.9M-1.45M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
171.44M9.07M43.18M-13.77M-18.96M13.64M-3.94M16.72M-31.13M-31.19M
Cash & Equivalents at Beginning of Year83.26M74.19M31.01M44.78M63.75M50.1M54.05M37.32M68.46M99.66M
Cash & Equivalents at Year End254.71M83.26M74.19M31.01M44.78M63.75M50.1M54.05M37.32M68.46M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

While Neurocrine Biosciences stock price history provides the price history of a stock, Neurocrine Biosciences stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Neurocrine Biosciences saw a positive change in Net Change in Cash and Cash Equivalents of $171.44M in 2017. Apart from the Neurocrine Biosciences stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • The cash generated from the core business or operations was a negative at $-94.33M for Neurocrine Biosciences in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Cash from investing stood at a negative value of $-250.87M for NBIX stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $516.64M for Neurocrine Biosciences. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Neurocrine Biosciences Cash Flow

FCF margin
0.16

Annual Cash Flow Statements For Neurocrine Biosciences, Inc. Peers

Nektar Therapeutics cash flow, Pfizer cash flow, Sage Therapeutics cash flow, Salix Pharma cash flow